These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9916886)

  • 21. Copolymer 1: from basic research to clinical application.
    Teitelbaum D; Arnon R; Sela M
    Cell Mol Life Sci; 1997 Jan; 53(1):24-8. PubMed ID: 9117994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin.
    Salehi M; Bagherpour B; Shayghannejad V; Mohebi F; Jafari R
    Iran J Immunol; 2016 Jun; 13(2):141-7. PubMed ID: 27350635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
    Jee Y; Liu R; Bai XF; Campagnolo DI; Shi FD; Vollmer TL
    Int Immunol; 2006 Apr; 18(4):537-44. PubMed ID: 16481342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine secretion profile of myelin basic protein-specific T cells in multiple sclerosis.
    Rohowsky-Kochan C; Molinaro D; Cook SD
    Mult Scler; 2000 Apr; 6(2):69-77. PubMed ID: 10773850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.
    Aharoni R; Teitelbaum D; Sela M; Arnon R
    J Neuroimmunol; 1998 Nov; 91(1-2):135-46. PubMed ID: 9846830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.
    Aharoni R; Teitelbaum D; Sela M; Arnon R
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10821-6. PubMed ID: 9380718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific vaccines against autoimmune diseases.
    Sela M
    C R Acad Sci III; 1999 Nov; 322(11):933-8. PubMed ID: 10646086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.
    Arnon R; Aharoni R
    Proc Natl Acad Sci U S A; 2004 Oct; 101 Suppl 2(Suppl 2):14593-8. PubMed ID: 15371592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients.
    Qin Y; Zhang DQ; Prat A; Pouly S; Antel J
    J Neuroimmunol; 2000 Aug; 108(1-2):201-6. PubMed ID: 10900354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunological study of IFNbeta-1a-treated and untreated multiple sclerosis patients: clarifying IFNbeta mechanisms and establishing specific dendritic cell immunotherapy.
    Berghella AM; Totaro R; Pellegrini P; Contasta I; Russo T; Carolei A; Adorno D
    Neuroimmunomodulation; 2005; 12(1):29-44. PubMed ID: 15756051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
    Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
    Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Th1/Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis.
    Rodríguez-Sáinz Mdel C; Sánchez-Ramón S; de Andrés C; Rodríguez-Mahou M; Muñoz-Fernández MA
    Eur Cytokine Netw; 2002; 13(1):110-4. PubMed ID: 11956029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis.
    Link J
    Acta Neurol Scand Suppl; 1994; 158():1-58. PubMed ID: 7732782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment.
    Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V
    J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):123-6. PubMed ID: 12486283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data.
    Johnson KP
    J Neurol; 1996 Apr; 243(4 Suppl 1):S3-7. PubMed ID: 8965118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.
    Aharoni R
    J Autoimmun; 2014 Nov; 54():81-92. PubMed ID: 24934599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis.
    Zang Y; Hong J; Robinson R; Li S; Rivera VM; Zhang JZ
    J Neuroimmunol; 2003 Apr; 137(1-2):144-53. PubMed ID: 12667659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate.
    Tumani H; Kassubek J; Hijazi M; Lehmensiek V; Unrath A; Süssmuth S; Lauda F; Kapfer T; Fang L; Senel M; Brettschneider J
    Eur Neurol; 2011; 65(3):164-9. PubMed ID: 21372576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis.
    Hussien Y; Sanna A; Söderström M; Link H; Huang YM
    J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [3-year results of clinical and immunological monitoring of patients with multiple sclerosis treated by copaxone].
    Orlova IuIu; Alifirova VM; Cherdyntseva NV; Zagrebina IA; Bychkova IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(5):23-7. PubMed ID: 15952536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.